MiNK Therapeutics, Inc. (INKT)
- Previous Close
0.8763 - Open
0.9051 - Bid 0.8405 x 100
- Ask 0.9381 x 100
- Day's Range
0.8620 - 0.9051 - 52 Week Range
0.7500 - 3.3400 - Volume
39,983 - Avg. Volume
99,422 - Market Cap (intraday)
31.021M - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6500 - Earnings Date May 11, 2024 - May 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
minktherapeutics.comRecent News: INKT
Performance Overview: INKT
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INKT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INKT
Valuation Measures
Market Cap
30.35M
Enterprise Value
26.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.19
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-110.10%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.46M
Diluted EPS (ttm)
-0.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.08M